IDEAYA Biosciences, Inc. (IDYA)

IDEAYA Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	7	23.39	50.93	27.94	19.54
Revenue Growth (YoY)	-70.07%	-54.09%	82.28%	43.01%	-
Cost of Revenue	294.67	129.51	89.54	58.16	39.7
Gross Profit	-287.67	-106.12	-38.61	-30.22	-20.16
Selling, General & Admin	39.3	28.31	23.9	20.05	15.18
Operating Expenses	39.3	28.31	23.9	20.05	15.18
Operating Income	-326.98	-134.43	-62.5	-50.27	-35.34
Interest & Investment Income	29.27	9.92	3.15	2.34	0.83
EBT Excluding Unusual Items	-297.71	-124.51	-59.35	-47.93	-34.51
Gain (Loss) on Sale of Investments	23.23	11.55	0.7	-1.83	0.02
Pretax Income	-274.48	-112.96	-58.66	-49.76	-34.5
Net Income	-274.48	-112.96	-58.66	-49.76	-34.5
Net Income to Common	-274.48	-112.96	-58.66	-49.76	-34.5
Shares Outstanding (Basic)	82	58	41	35	25
Shares Outstanding (Diluted)	82	58	41	35	25
Shares Change (YoY)	42.00%	38.79%	17.57%	42.60%	97.82%
EPS (Basic)	-3.36	-1.96	-1.42	-1.41	-1.40
EPS (Diluted)	-3.36	-1.96	-1.42	-1.41	-1.40
Free Cash Flow	-251.44	-117.59	-90.62	-58.42	54.97
Free Cash Flow Per Share	-3.08	-2.04	-2.19	-1.66	2.22
Gross Margin	-	-	-75.80%	-108.15%	-103.18%
Operating Margin	-4671.07%	-574.85%	-122.72%	-179.91%	-180.90%
Profit Margin	-3921.10%	-483.05%	-115.17%	-178.10%	-176.55%
Free Cash Flow Margin	-3592.01%	-502.85%	-177.92%	-209.09%	281.35%
EBITDA	-324.59	-131.95	-60.4	-48.54	-33.96
EBITDA Margin	-	-	-118.59%	-173.73%	-173.83%
D&A For EBITDA	2.39	2.48	2.1	1.73	1.38
EBIT	-326.98	-134.43	-62.5	-50.27	-35.34
EBIT Margin	-	-	-122.72%	-179.91%	-180.90%
Revenue as Reported	7	23.39	50.93	27.94	19.54

Updated Feb 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q